sodium phosphate

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Related to hyperphosphatemia, unless otherwise indicated

CV: ECG changes (absent P waves, widening of the QRS complex with biphasic curve), ARRHYTHMIAS, CARDIAC ARREST, hypotension; hypernatremia: edema

F and E: hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia, hypomagnesemia

GI: diarrhea, abdominal pain, nausea, vomiting

Local: irritation at IV site, phlebitis

MS: hypocalcemia: tremors

Neuro: confusion, flaccid paralysis, heaviness of legs, listlessness, paresthesias of extremities, weakness

Resp: hypernatremia: shortness of breath

Interactions ⬆ ⬇

Drug-drug:

Concurrent use ofcorticosteroids with sodium phosphate may result in hypernatremia.

Availability ⬆ ⬇

(Generic available)

IV injection for dilution: 3 mmol phosphate and 4 mEq sodium/mL in 10-, 15-, 30-, and 50-mL vials

Route/Dosage ⬆ ⬇

IV (Adults ): 12–15 mmol phosphorus/liter of parenteral nutrition.
IV (Children ): Hypophosphatemia: 0.08–0.36 mmol/kg over 6 hrs;Maintenance: <25 kg: 0.5–1.5 mmol/kg/day; 25–45 kg: 0.5–1 mmol/kg/day.
IV (Neonates ): Maintenance: 0.8–1.5 mmol/kg/day (infused as part of parenteral nutrition).

Action ⬆ ⬇

Phosphate is present in bone and is involved in energy transfer and carbohydrate metabolism.
Serves as a buffer for the excretion of hydrogen ions by the kidney.

Therapeutic effects:

Classifications ⬆ ⬇

Therapeutic Classification: mineral and electrolyte replacements/supplements

Pharmacologic Classification: phosphate supplements

Pharmacokinetics ⬆ ⬇

Absorption: Administered IV only, resulting in complete bioavailability.

Distribution: Phosphates enter extracellular fluids and are then actively transported to sites of action.

Metabolism/Excretion: Excreted mainly (>90%) by the kidneys.

Half-Life: Unknown.

ROUTE	ONSET	PEAK	DURATION
IV	rapid (min–hr)	end of infusion	unknown